The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Celgene; Halozyme; TYME
Research Funding - ArQule (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Imke Mulder
Employment - 4D Pharma
Stock and Other Ownership Interests - 4D Pharma
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Pavlos Msaouel
Research Funding - Bristol-Myers Squibb (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Mehmet Altan
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
 
John Weinberg
Employment - 4D Pharma
Stock and Other Ownership Interests - 4D Pharma
 
Alex Stevenson
Employment - 4D Pharma
Stock and Other Ownership Interests - 4D Pharma
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; Genentech; Inflection Biosciences; Mersana; Origimed; Pieris Pharmaceuticals; Samsung Bioepis; Spectrum Pharmaceuticals; Xencor
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim (I); Calithera Biosciences; Curis; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; eFFECTOR Therapeutics; Genentech; GlaxoSmithKline; Guardant Health (Inst); Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Timothy A Yap
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - EMD Serono; Pfizer; Tesaro
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Kelun; Lilly/ImClone; Merck Sharp & Dohme; Novartis; Orion; Peptomyc; Pfizer; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; Novartis